Table 2. Clinicopathological characteristics of all patients according both cut off satisfaction.
| Characteristics | High-ratio group (n = 44) | Low-ratio group (n = 61) | p-value | |
|---|---|---|---|---|
| Age (mean, yr) | 50.3 ± 9.0 | 51.7 ± 10.0 | 0.456 | |
| ≤ 50 | 21 (47.7) | 26 (42.6) | 0.604 | |
| > 50 | 23 (52.3) | 35 (57.4) | ||
| HG | 0.455 | |||
| I | 2 (4.8) | 5 (8.6) | ||
| II, III | 40 (95.2) | 53 (91.4) | ||
| Unknown | 2 | 3 | ||
| ER | 0.706 | |||
| Positive | 24 (54.6) | 31 (50.8) | ||
| Negative | 20 (45.4) | 30 (49.2) | ||
| PR | 0.831 | |||
| Positive | 21 (47.7) | 27 (44.3) | ||
| Negative | 23 (52.3) | 34 (55.7) | ||
| HER-2 | 0.504 | |||
| Positive | 13 (35.1) | 22 (37.3) | ||
| Negative | 24 (64.9) | 37 (62.7) | ||
| Unknown | 7 | 2 | ||
| Ki67* | 0.034† | |||
| Low | 0 (0.0) | 10 (16.4) | ||
| Intermediate | 10 (23.3) | 8 (13.1) | ||
| High | 33 (76.7) | 43 (70.5) | ||
| Unknown | 1 | 0 | ||
| Clinical tumor size | 0.958 | |||
| ≤ 2 cm | 3 (6.8) | 4 (6.6) | ||
| > 2 cm | 41 (93.2) | 57 (93.4) | ||
| Clinical LN involvement | 0.825 | |||
| Positive | 34 (77.3) | 46 (75.4) | ||
| Negative | 10 (22.7) | 15 (24.6) | ||
| NAC response | 0.002† | |||
| NAC non-response | 37 (84.1) | 34 (55.7) | ||
| NAC response | 7 (15.9) | 27 (44.3) | ||
HG = histologic grade; ER = estrogen receptor; PR = progesterone receptor; LN = lymph node; NAC = neoadjuvant chemotherapy.
*Ki67: low for < 10%, intermediate for 10–20, high for > 20% tumor cells. †The p-values with statistically significance.